| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
May 18, 2017First-Ever Study on 2.0 mm DES, EuroPCR Late-Breaking Data Show Exceptional Deliverability and No Stent Thrombosis for the Resolute Onyx DES
DUBLIN and PARIS- May 18, 2017 - Medtronic plc (NYSE: MDT) today announced that the Resolute Onyx(TM) Drug-Eluting Stent (DES) met its primary endpoint of Target Lesion Failure (TLF) at one year...
-
May 1, 2017Engineered for Exceptional Deliverability, Advanced DES Technology Features Thinner Struts, Enhanced Visibility and the Broadest Size Matrix in the U.S.
DUBLIN – May 1, 2017 – Medtronic plc (NYSE: MDT) today announced the U.S. Food and Drug Administration (FDA) approval and U.S. launch of the Resolute Onyx™ Drug-Eluting Stent (DES). The...
-
Feb 13, 2017Full Line of Innovative Transradial Products and Comprehensive Training Programs Reinforce Medtronic's Commitment to Optimizing the Treatment of Heart Disease
DUBLIN - Feb. 13, 2017 - Medtronic plc (NYSE: MDT) today announced that its market-leading coronary portfolio will now include the DxTerity Diagnostic Angiography Catheter line and several...
-
Oct 31, 2016Featured 'First Report' RevElution Trial at TCT Highlights the Potential Benefits of First-of-its-Kind Polymer-Free Technology with Controlled and Sustained Drug Delivery for Rapid Vessel Healing
DUBLIN and WASHINGTON, D.C. - Oct. 31, 2016 - Medtronic plc (NYSE: MDT) unveiled today the first clinical outcomes of its novel Drug-Filled Stent (DFS) from the RevElution Trial at the...
-
Apr 3, 2016Medtronic Announces Early Data and Completes Enrollment in CE Mark Cohort in Drug-Filled Stent TrialRevElution Trial with Next-Gen Polymer-Free Stent Continues to Show Excellent Rapid Healing and Controlled Drug Delivery at ACC.16
DUBLIN and CHICAGO - April 3, 2016 - Medtronic plc (NYSE: MDT) announced new clinical data today from one of the endpoints in the RevElution Trial for its novel, next-generation Drug-Filled Stent...
-
Feb 1, 2016New Extra-Large Vessel Stent Sizes and Indications in the EU Expand Treatment Options for Patients with Coronary Artery Disease
DUBLIN - February 1, 2016 - Medtronic plc (NYSE: MDT) today announced the recent CE (Conformité Européene) Mark and commercial launch for an expanded size matrix of the Resolute Onyx DES, a next...
-
Nov 30, 2014First and Only DES with Novel CoreWire Technology Allows for Thinner, Stronger Struts, Enhanced Deliverability and Radiopacity without Compromising Structural Strength
MINNEAPOLIS - Nov. 3, 2014 - Optimizing the treatment of coronary artery disease with a new foundation for future stent innovations, Medtronic, Inc. (NYSE: MDT) today announced CE (Conformité Europé
-
Nov 5, 2014Fourth-quarter net sales up 7%; Medical Devices sales up 8%
DUBLIN, Ireland--(BUSINESS WIRE)--Nov. 5, 2014-- Covidien plc (NYSE: COV) today announced financial results for the fourth quarter of fiscal 2014. Fourth-quarter net sales of $2.73 billion...
-
Sep 11, 2014Superior Deliverabilityi and Uncompromising Performance Distinguishes New Angioplasty Balloon
MINNEAPOLIS -- Sept. 11, 2014 -- Medtronic, Inc. (NYSE: MDT) today announced the U.S. Food and Drug Administration (FDA) 510(k) clearance and launch of the NC Euphora(TM) Noncompliant Balloon...
-
Jul 25, 2014Net sales up 4%; Medical Devices sales up 5%
DUBLIN, Ireland--(BUSINESS WIRE)--Jul. 25, 2014-- Covidien plc (NYSE: COV) today announced financial results for the third quarter of fiscal 2014. Third-quarter net sales of $2.69 billion...